🔎 Trials Near Me

Home › Atrial Flutter › NCT07632157

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation

RecruitingPhase 3

MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age \> 18 years or older
* Able to provide informed consent
* Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
* Metoprolol as rate control agent
* English speaking

Exclusion Criteria:

* Hemodynamically unstable patients (SBP \<90, MAP \<65)
* Impaired consciousness
* Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
* Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
* Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
* Acute myocardial infarction
* Contraindications to magnesium sulfate (including myasthenia gravis)
* Allergy or sensitivity to any study drugs
* Previously enrolled in this trial during a different patient encounter
* Withdrew from study

About the study

The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).

What is being tested

Sponsor: Wake Forest University Health Sciences · Participants: 196 · Started: Nov 10, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07632157

Locations in the U.S.

IllinoisAdvocate Christ Medical Center Emergency Department (ACMC ED), Oak Lawn

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.